The discovery of the Na+-dependent allosteric regulation in serine pro
teases makes it possible to control catalytic activity and specificity
in this class of enzymes in a way never considered before. We demonst
rate that rational site-directed mutagenesis of residues controlling N
a+ binding can profoundly alter the properties of a serine protease. B
y suppressing Na+ binding to thrombin, we shift the balance between pr
ocoagulant and anticoagulant activities of the enzyme. Those mutants,
compared to wild-type, have reduced specificity toward fibrinogen, but
enhanced or slightly reduced specificity toward protein C. Because th
is engineering strategy targets a fundamental regulatory mechanism, it
is amenable of extension to other enzymes of biological and pharmacol
ogical importance.